You are leaving this site. You are about to leave www.grantforfertilityinnovation.com. The content of the site you are about to visit is not controlled by grantforfertilityinnovation.com.

Jie Li

Jie Li

Dr Jie LI - Human Reproductive Center, First Affiliated Hospital of Sun Yat-Sen University, CHINA

Prof Li Jie has been working as a doctor in Gyneology and Obstetris Department after graduated from XiangYa Medical Collage since 1985. She has beginning major on the Reproductive Endocrinology and Human Assisted Reproductive Technology from 1991 in SunYat-Sen University Medical Sciences. She had got the diploma of the PH.D of Reproductive Medicine in 1999 and has been trained in Weirs’ Prince Hospital of Hong Kong Chinese University, National University of Singapore, Peking Union Medical College Hospital Beijing of China and City West IVF Center in Sydney, Australia receptivity.

She was the first successful person on the project of Oocyte donation in POF patients in China and Mild Down Regulation of micro-dose long-acting GnRH-a protocol in IVF-ET program in the world. She also is Cooperator Professors of State Key Laboratory of Reproductive Biology Institute of Zoology of Chinese Academy of Science in China and Specialist of Sheffield Hallam University in Sheffield. UK. She is a Committee Membership of Authority, Ethics and Management of Reproductive Medical Association in China and a member of Review committee of National or GuangDong Province Natural Science Foundation and Assisted Reproductive Technology Review of the Ministry of Health in China. She is also as a Editor or Manuscript Reviewer for several Journal and a committee resume of Advisory Committee Member of Diphereline IVF Training Course in China from 2005 to 2013.

As a Principal or Main Participator Investigator, she has been got or successful finished 8 and 5 Projects respectively. She also got the First Honor Awards in two project and three Participator Awards in GuangDong Province and in China.

Prof Li Jie has been published more than 40 articles or 20 abstracts correlated in this field as the First or Corresponding Author, as one of the editor for 5 Book in China, and was invited as a speaker in international or national meeting more than 30 times in five years.

Project: Utilization of Electrochemiluminescence immunoassay (ECLIA ) for the detection of Early Embryonic Biomarkers for Embryo Selection

In assisted reproductive technology (ART), the grading systems based on morphology and stage of embryo development has been the primarycriteria to identify the embryos with high competence to transfer.However, morphological evaluations are subjective and imprecise and not always in accordance with embryo implantation potential. Other invasive and non-invasive methods such as genomics, proteomic and metabolomic profiles of spent culture media were explored for embryo assessment but unfortunately none of them gave conclusive results.

Some of the mot simple and obvious biomarkers with potential to add information in the detection of highly viable embryos were not taken in consideration. Hyperglicosylated -hCG is one of the first embryonic signals of viable blastomeric/trophoblastic cells to the endometrium and this molecule was detected by different investigators in culture media containing embryos at different stages of embryo development (day 2 to 5).

Different technologies were utilized to detect H-hCG but the sensitivity and repeatability of the diagnosis was a major limitation factor. Electrochemiluminescence immunoassay (ECLIA) technology is a method based on solid-phase sandwich immunoassay with advantages of superior sensitivity to detect different molecules including H-hCG levels of 0.100mIU/ml in plasma or urine samples, taking only 20 minutes for the completion of the assay.

The aim of this project is to evaluate the profile of H-hCG levels secreted by individual fresh and frozen/thawed embryos and detected by a modified electrochemiluminescence immunoassay (ECLIA) in spent embryo culture media from day1 to day6 of culture. We also aim to explore it’s utilization as a complementary biomarker for embryo competence assessment in clinical IVF-ET procedure.